In summary, our investigation supports a role for BRCA2 and HOXB13 mutations in prostate cancer predisposition and provides reassurance that BRCA1, RNASEL, and ELAC2 are not substantially contributory in this cohort. The gene discussed is ELAC2; the disease is Familial prostate cancer.